Detection and characterization of classical and "uncommon" exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing. - Wikidata - wikimedia - TriplyDB

Detection and characterization of classical and "uncommon" exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing.

Detection and characterization of classical and "uncommon" exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing.

http://www.wikidata.org/entity/Q34622721

about

Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma.Preanalytic parameters in epidermal growth factor receptor mutation testing for non-small cell lung carcinoma: A review of cytologic series Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients.Molecular and Histological Changes in Post-Treatment Biopsies of Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Study.

P2860

Q36088709-EF27E302-B214-44DB-B4D5-44393DB2EF9D Q37296060-53018C30-79C1-46E1-90D3-15EB9C1259ED Q44070495-E05BA4B3-CD59-478E-9C7C-10242B8CD53C Q52921226-4721F47E-AE92-4CDE-97EB-255E7D90E68B

P2860

Detection and characterization of classical and "uncommon" exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing.

http://www.wikidata.org/entity/Q34622721

description

2013 nî lūn-bûn

@nan

2013 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մարտին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Detection and characterization ...... lung cancer by pyrosequencing.

@ast

Detection and characterization ...... lung cancer by pyrosequencing.

@en

Detection and characterization ...... lung cancer by pyrosequencing.

@nl

type

label

Detection and characterization ...... lung cancer by pyrosequencing.

@ast

Detection and characterization ...... lung cancer by pyrosequencing.

@en

Detection and characterization ...... lung cancer by pyrosequencing.

@nl

prefLabel

Detection and characterization ...... lung cancer by pyrosequencing.

@ast

Detection and characterization ...... lung cancer by pyrosequencing.

@en

Detection and characterization ...... lung cancer by pyrosequencing.

@nl

P1433

Q34622721-68D8A0A1-4556-4751-829E-4F3D1B63DE89

P1476

Q34622721-2054BAB8-F5E1-4CEE-8E46-61B1C3704DFE

P2093

Q34622721-1C6EED35-44CE-438E-BD5D-BD66A9F2364F

Q34622721-299D3983-CD2C-4E85-99A3-B1E4BFF269F8

Q34622721-29B61786-AA60-4580-BBD6-745BCD6C0450

Q34622721-4D01AA5B-12E5-4247-8AD4-D5AF09F1689E

Q34622721-6978E8ED-7E3D-48D9-AF66-0503C3F9749F

Q34622721-9555C075-5562-46B5-A26C-60C91A3FCAA3

Q34622721-A81A128F-C1B4-4771-BE17-8584D567DFF7

Q34622721-B6499C57-CE2B-4ECA-A483-ADDDD576157D

Q34622721-E8F12A2E-E8E2-453C-93E8-D352C73BD192

P2860

Q34622721-0ABF8BF8-DECA-4C28-A27B-6F082EA2729C

Q34622721-0BEE6FB5-CB4A-4F74-A25E-93D7B25198E5

Q34622721-0C82CE95-4F7E-4A6B-B769-087E95BB383C

Q34622721-1C40E073-A701-4CA6-BA4C-6D940A0D412C

Q34622721-27C5B425-A22D-44B3-8082-1B20C7BFE264

Q34622721-2A5222FF-4F60-4764-9132-DC318274E45B

Q34622721-31C95A07-B9A1-45A0-B889-9BBE4FBDEE10

Q34622721-36EB393B-9C72-4A69-A293-520350C9A9AA

Q34622721-3E0F2489-6F9A-4EDA-B528-245049E2ED3B

Q34622721-43CF4458-291D-45E6-A309-41E0F71053C6

P2888

Q34622721-9CAB5A35-3A2B-460F-8787-BE2D6D95EF5A

P304

Q34622721-B1A9E42A-CB70-4062-93FD-F6641AC8CA69

P31

Q34622721-B3C780FD-F227-4647-A7B6-2F823A36B248

P356

Q34622721-368E0825-6D5D-4462-8B27-7E863DFA083A

P407

Q34622721-8C789BA3-03CD-4EC8-84D4-2D1EDD1A54D0

P478

Q34622721-468D1A46-4624-475B-91A5-11A2CF296304

P50

Q34622721-0BF07775-36A9-4C04-A53C-993E71A15384

Q34622721-C38143C9-6BA5-488A-936C-52C058263A28

P577

Q34622721-1A050C5A-39CA-4292-BE07-2ED3727FA017

P5875

Q34622721-AB8457C1-C8EB-4314-AFB3-B6DDEEE92A3C

P6179

Q34622721-0DD7BEC1-4A7D-4727-961B-84CB4E7D8F5D

P698

Q34622721-8AD1CBAD-FB5E-43AD-B71C-8A6C6D3B487E

P932

Q34622721-A262486F-B139-45AF-A3E0-97DB501A4D57

P356

1471-2407-13-114

P1433

P1476

Detection and characterization ...... lung cancer by pyrosequencing

@en

P2093

Alessandra Cuccurullo

http://www.w3.org/2001/XMLSchema#string

Giorgio V Scagliotti

http://www.w3.org/2001/XMLSchema#string

Mara Ardine

http://www.w3.org/2001/XMLSchema#string

Marco Volante

http://www.w3.org/2001/XMLSchema#string

Mauro Papotti

http://www.w3.org/2001/XMLSchema#string

Paolo De Giuli

http://www.w3.org/2001/XMLSchema#string

Silvia Novello

http://www.w3.org/2001/XMLSchema#string

Simona Vatrano

http://www.w3.org/2001/XMLSchema#string

Susanna Cappia

http://www.w3.org/2001/XMLSchema#string

P2860

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

Benchmarking of mutation diagnostics in clinical lung cancer specimens

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC.

Molecular modeling and description of a newly characterized activating mutation of the EGFR gene in non-small cell lung cancer.

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond.

Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.

Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing.

P2888

1471-2407-13-114

P304

114

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-13-114

http://www.w3.org/2001/XMLSchema#string

P407

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Daniela Giachino

P577

2013-03-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236051578

http://www.w3.org/2001/XMLSchema#string

P6179

1013365056

http://www.w3.org/2001/XMLSchema#string

P698

23497146

http://www.w3.org/2001/XMLSchema#string

P932

3608975

http://www.w3.org/2001/XMLSchema#string